Last reviewed · How we verify
standard-dose ticagrelor
standard-dose ticagrelor is a P2Y12 receptor antagonist Small molecule drug developed by First Affiliated Hospital of Harbin Medical University. It is currently FDA-approved for Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis, Secondary prevention of atherothrombotic events in patients with prior myocardial infarction.
Ticagrelor is a P2Y12 receptor antagonist that irreversibly blocks platelet activation and aggregation, reducing thrombotic events.
Ticagrelor is a small molecule that acts as a negative allosteric modulator of the P2Y purinoceptor 12, a type of purinergic receptor. It is used in standard-dose form for conditions such as coronary artery disease and coronary stenoses, typically in combination with aspirin.
At a glance
| Generic name | standard-dose ticagrelor |
|---|---|
| Sponsor | First Affiliated Hospital of Harbin Medical University |
| Drug class | P2Y12 receptor antagonist |
| Target | P2Y12 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor binds directly and reversibly to the P2Y12 adenosine diphosphate (ADP) receptor on platelets, preventing platelet activation and aggregation. Unlike clopidogrel, it does not require hepatic metabolism for activation and provides faster onset of action. This results in reduced platelet-mediated thrombosis and lower risk of cardiovascular events in acute coronary syndromes and other thrombotic conditions.
Approved indications
- Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis
- Secondary prevention of atherothrombotic events in patients with prior myocardial infarction
Common side effects
- Bradycardia
- Dyspnea
- Bleeding (major and minor)
- Ventricular pauses
Key clinical trials
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention (PHASE4)
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
- Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
- Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease (PHASE4)
- TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI (PHASE4)
- Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- standard-dose ticagrelor CI brief — competitive landscape report
- standard-dose ticagrelor updates RSS · CI watch RSS
- First Affiliated Hospital of Harbin Medical University portfolio CI
Frequently asked questions about standard-dose ticagrelor
What is standard-dose ticagrelor?
How does standard-dose ticagrelor work?
What is standard-dose ticagrelor used for?
Who makes standard-dose ticagrelor?
What drug class is standard-dose ticagrelor in?
What development phase is standard-dose ticagrelor in?
What are the side effects of standard-dose ticagrelor?
What does standard-dose ticagrelor target?
Related
- Drug class: All P2Y12 receptor antagonist drugs
- Target: All drugs targeting P2Y12
- Manufacturer: First Affiliated Hospital of Harbin Medical University — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis
- Indication: Drugs for Secondary prevention of atherothrombotic events in patients with prior myocardial infarction
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing